BI-3406 is a potent and selective inhibitor of the SOS1-KRAS interaction that attenuates reactivation by MEK inhibitors and enhances the sensitivity of KRAS-dependent cancers to MEK inhibition in preclinical models. This evidence concerns the gene MAP2K7 and cancer.